Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can western patients skip surgery for early stomach cancer?

NCT ID NCT07781319

Knowledge-focused Sponsor: Corporacion Parc Tauli Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 24, 2026 · Last updated Aug 25, 2026 · Updated 1 time

Summary

This study looks at early gastric cancer, a disease where the tumor is confined to the stomach's inner layers. It asks whether the pre-surgery assessment (clinical staging) matches the actual findings after surgery (pathological staging) in a large group of Western patients. The research also checks if Asian guidelines for minimally invasive endoscopic removal are suitable for these patients, and tracks long-term outcomes like recurrence and survival. By analyzing data from 600 people in a Spanish registry, the goal is to improve treatment decisions and reduce unnecessary procedures.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could refine treatment decisions for early gastric cancer in Western populations, potentially reducing unnecessary surgeries or improving outcomes.
What could go wrong
This is a retrospective observational study, so it cannot prove cause and effect. Results may not apply to all patients or regions, and the analysis depends on the accuracy of existing medical records.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

600 people

The number who actually took part.

Started

Jan 2014

Finished

Dec 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of adult patients with a preoperative clinical diagnosis of early gastric cancer (cT1) who underwent curative-intent gastrectomy with lymph node dissection at participating centers of the Spanish EURECCA Registry between January 2014 and December 2022. The cohort includes patients with histologically confirmed gastric adenocarcinoma and complete clinicopathological and follow-up data available for analysis. This population was selected to evaluate the accuracy of preoperative clinical staging and to investigate the pathological characteristics and oncological outcomes of early gastric cancer in a Western multicenter cohort.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults (≥18 years of age) * Clinical diagnosis of early gastric cancer (cT1) before surgery. * Curative-intent gastrectomy with lymph node dissection performed between * January 2014 and December 2022. * Histologically confirmed gastric adenocarcinoma. * Inclusion in the multicenter Spanish EURECCA Registry. * Availability of complete preoperative clinical staging, pathological findings, and follow-up data required for the study analyses. Exclusion Criteria: * Receipt of neoadjuvant therapy before surgery. * Incomplete pathological data precluding accurate tumor staging or lymph node assessment. * Non-adenocarcinoma gastric tumors.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Early gastric cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastric neoplasm Lymphatic Metastasis microinvasive gastric cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Early gastric cancer Gastric adenocarcinoma

More trials for these conditions

Other studies related to the condition(s) this trial covers.